Скачать или смотреть The future of CSF liquid biopsies in precision medicine for brain tumors

Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, highlights the emerging role cell-free DNA (cfDNA) as novel biomarkers in neuro-oncology, highlighting their ability to detect molecularly defined biomarkers and monitor treatment response. Cerebrospinal fluid (CSF) and plasma are in a new paradigm for precision medicine, enabling longitudinal monitoring of molecular alterations and treatment response, and potentially leading to more effective and personalized treatment strategies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.